We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Ingenuity Announces Availability of Ingenuity Pathways Analysis 3.0

Want a FREE PDF version of this product news?

Complete the form below and we will email you a PDF version of "Ingenuity Announces Availability of Ingenuity Pathways Analysis 3.0"

Listen with
Register for FREE to listen to this article
Thank you. Listen to this article using the player above.
Read time:

Ingenuity has announced the release and immediate availability of Ingenuity Pathways Analysis 3.0.

According to Ingenuity, the fundamentally re-designed Ingenuity Pathways Analysis 3.0 is a next generation pathways tool, enabling life science researchers to model, analyze and understand complex biological systems and enhancing the productivity of pharmaceutical research and development.

IPA 3.0 is designed to analyze microarray and proteomics data in the context of pathways.

It Compares changes in biological states across time and dosages and derives biological function from genomic/proteomic data sets.

IPA 3.0 creates customized pathways for targets, biomarkers, processes and diseases.

It integrates personal insights into any pathway, also integrates proprietary relationships into any pathway and analyzes customized pathways to derive biological function.

IPA 3.0 assists in search based on genes, proteins, diseases, processes, functions, and identifiers.

It Uses search results to build pathways and expands pathways to build and test hypotheses.

Ingenuity claims that, with the help of IPA 3.0 scientists can share analyses, personalized pathways and insights with colleagues.

They can also create virtual communities for sharing and receiving pathway insights.

"IPA 3.0 is a remarkable step forward in the ability of researchers to understand complex biology," said Dr. Ron Davis, Professor of Biochemistry and Genetics and Director of the Stanford Genome Technology Center.

"It will define how people think about pathways in basic science and translational medicine and undoubtedly become a vital tool in academic and pharmaceutical research."

Ingenuity Pathways Analysis 3.0 is immediately available as a web-based application or as a customized and deployed solution, and is supported with global customer support and training.

"I am enormously proud of the Ingenuity team for their hard work and commitment to making Ingenuity Pathways Analysis 3.0 a reality," said Jake Leschly, Chief Executive Officer of Ingenuity Systems.

"Ingenuity Pathways Analysis 3.0 is a major step in Ingenuity's seven years of product innovation, and represents the insights and feedback from thousands of users on ways to make IPA an even more powerful solution for delivering insights to scientists and enhanced productivity to our pharmaceutical and biotech customers."